Rabeprazole Sodium Tablet, Delayed Release
Product Images NDC 71335-2304

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Rabeprazole Sodium (NDC 71335-2304). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713352304)

Label for RABEprazole Sodium 20 mg delayed-release tablets, oral administration, repackaged by Bryant Ranch Prepack and manufactured by Rubicon Research Private Limited. The label includes a barcode, NDC 71335-2304-2, and states a package size of 90 tablets. Storage instructions and medication guide information are also visible.*

FDA Label Image

Structural Image (Rabeprazole Dr Tablet 01)

Chemical structure of rabeprazole sodium, the active ingredient in RABEPRAZOLE SODIUM 20 mg delayed-release oral tablets by Bryant Ranch Prepack.*

FDA Label Image

Figure 2: Mean Daytime Heartburn Scores Rab-usa-2 (Rabeprazole Dr Tablet 02)

A line graph depicting heartburn mean scores over a 28-day study comparing placebo, rabeprazole sodium 10 mg, and rabeprazole sodium 20 mg groups. The x-axis represents study days before and after treatment starts (day 0), and the y-axis shows mean heartburn severity scores from 0 (none) to 4 (very severe).*

FDA Label Image

Figure 3: Mean Nighttime Heartburn Scores Rab-usa-2 (Rabeprazole Dr Tablet 03)

A line chart depicting mean heartburn scores over a 28-day study period comparing three groups: placebo, rabeprazole 10 mg, and rabeprazole 20 mg. The x-axis represents study days from -14 to 28, and the y-axis shows mean heartburn scores ranging from 0 (none) to 4 (very severe).*

FDA Label Image

Figure 4: Mean Daytime Heartburn Scores Rab-usa-3 (Rabeprazole Dr Tablet 04)

A line graph comparing mean heartburn scores over time between a placebo group and a group receiving 20 mg RABEPRAZOLE sodium. The x-axis represents study days, and the y-axis shows mean heartburn scores ranging from 0 (none) to 4 (very severe). The graph depicts symptom changes before and after treatment initiation.*

FDA Label Image

Figure 5: Mean Nighttime Heartburn Scores Rab-usa-3 (Rabeprazole Dr Tablet 05)

A line graph comparing mean heartburn scores over a 28-day study period for two groups: placebo (n=58) and rabeprazole sodium 20 mg (n=59). The x-axis represents study days, from -14 to 28, and the y-axis shows mean heartburn scores rated from 0 (None) to 4 (Very Severe). The graph illustrates decreasing heartburn scores in both groups over time, with lower scores in the rabeprazole 20 mg group compared to placebo after day 0.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.